Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33 (2022).

Article  PubMed  Google Scholar 

Webb, P. M. & Jordan, S. J. Global epidemiology of epithelial ovarian cancer. Nat. Rev. Clin. Oncol. 21, 389–400 (2024).

Article  PubMed  Google Scholar 

Lheureux, S., Gourley, C., Vergote, I. & Oza, A. M. Epithelial ovarian cancer. Lancet 393, 1240–1253 (2019).

Article  PubMed  Google Scholar 

Clair, K. H., Wolford, J., Zell, J. A. & Bristow, R. E. Surgical management of gynecologic cancers. Surg. Oncol. Clin. N. Am. 30, 69–88 (2021).

Article  PubMed  Google Scholar 

Ledermann, J. A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv259 (2018).

Article  CAS  PubMed  Google Scholar 

Coleridge, S. L., Bryant, A., Kehoe, S. & Morrison, J. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst. Rev. 7, CD005343 (2021).

PubMed  Google Scholar 

Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495–2505 (2018).

Article  CAS  PubMed  Google Scholar 

Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484–2496 (2011).

Article  CAS  PubMed  Google Scholar 

Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416–2428 (2019).

Article  CAS  PubMed  Google Scholar 

Narod, S. Can advanced-stage ovarian cancer be cured? Nat. Rev. Clin. Oncol. 13, 255–261 (2016).

Article  CAS  PubMed  Google Scholar 

Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makker, V. et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N. Engl. J. Med. 386, 437–448 (2022).

Article  CAS  PubMed  Google Scholar 

Colombo, N. et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N. Engl. J. Med. 385, 1856–1867 (2021).

Article  CAS  PubMed  Google Scholar 

Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).

Article  Google Scholar 

Konecny, G. E. et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J. Natl Cancer Inst. 106, dju249 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198–5208 (2008).

Article  CAS  PubMed  Google Scholar 

Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).

Article  CAS  PubMed  Google Scholar 

Adams, S. F. et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 115, 2891–2902 (2009).

Article  PubMed  Google Scholar 

Hao, J., Yu, H., Zhang, T., An, R. & Xue, Y. Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis. Ther. Adv. Med. Oncol. 12, 1758835920967241 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ovarian Tumor Tissue Analysis, C. et al. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. 3, e173290 (2017).

Article  Google Scholar 

Sato, E. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102, 18538–18543 (2005).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bobisse, S. et al. Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer. Nat. Commun. 9, 1092 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Anadon, C. M. et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell 40, 545–557.e13 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duraiswamy, J. et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell 39, 1623–1642.e20 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strickland, K. C. et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 7, 13587–13598 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Bruand, M. et al. Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Rep. 36, 109412 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamanishi, J. et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33, 4015–4022 (2015).

Article  CAS  PubMed  Google Scholar 

Hamanishi, J. et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J. Clin. Oncol. 39, 3671–3681 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Varga, A. et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol. Oncol. 152, 243–250 (2019).

Article  CAS  PubMed  Google Scholar 

Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080–1087 (2019).

Article  CAS  PubMed  Google Scholar 

Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu, J. F. et al. Safety, clinical activity and biomarker assessments of atezolizumab from a phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol. Oncol. 154, 314–322 (2019).

Article  CAS  PubMed